Bernice Matusow

2.9k total citations · 1 hit paper
13 papers, 1.4k citations indexed

About

Bernice Matusow is a scholar working on Molecular Biology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Bernice Matusow has authored 13 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Hematology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bernice Matusow's work include Protein Degradation and Inhibitors (7 papers), Multiple Myeloma Research and Treatments (5 papers) and Histone Deacetylase Inhibitors Research (4 papers). Bernice Matusow is often cited by papers focused on Protein Degradation and Inhibitors (7 papers), Multiple Myeloma Research and Treatments (5 papers) and Histone Deacetylase Inhibitors Research (4 papers). Bernice Matusow collaborates with scholars based in United States, Canada and Belgium. Bernice Matusow's co-authors include Hoa Nguyen, Monica R. P. Elmore, Nabil N. Dagher, Elizabeth E. Spangenberg, Kim N. Green, Masashi Kitazawa, Allison R. Najafi, Maya A. Koike, Brian L. West and Rachel Rice and has published in prestigious journals such as Neuron, Journal of Clinical Oncology and Blood.

In The Last Decade

Bernice Matusow

11 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain

2014 1.4k citations Monica R. P. Elmore, Allison R. Najafi et al. Neuron profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bernice Matusow United States	5	1.2k	584	243	230	226	13	1.4k
Frederick W. Gergits United States	5	1.2k 1.0×	653 1.1×	199 0.8×	202 0.9×	201 0.9×	6	1.4k
Connor Dufort United States	4	1.1k 1.0×	652 1.1×	199 0.8×	194 0.8×	166 0.7×	4	1.4k
Julia Bruttger Germany	7	1.1k 0.9×	671 1.1×	254 1.0×	186 0.8×	163 0.7×	10	1.4k
Kathleen Grabert Sweden	10	918 0.8×	510 0.9×	146 0.6×	233 1.0×	167 0.7×	16	1.2k
DeRen Huang United States	8	1.0k 0.9×	609 1.0×	151 0.6×	219 1.0×	226 1.0×	8	1.6k
Marta Olah United States	17	1.0k 0.9×	609 1.0×	279 1.1×	393 1.7×	190 0.8×	25	1.7k
Maria Gabriela Sánchez Canada	5	645 0.5×	288 0.5×	215 0.9×	168 0.7×	249 1.1×	7	976
Sol Beccari Spain	5	775 0.7×	412 0.7×	258 1.1×	153 0.7×	138 0.6×	5	982
Zain Fanek United States	3	1.7k 1.4×	1.0k 1.7×	273 1.1×	381 1.7×	228 1.0×	6	2.2k
Gilad Kunis Israel	11	861 0.7×	332 0.6×	146 0.6×	450 2.0×	193 0.9×	15	1.2k

Countries citing papers authored by Bernice Matusow

Since Specialization

Citations

This map shows the geographic impact of Bernice Matusow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernice Matusow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernice Matusow more than expected).

Fields of papers citing papers by Bernice Matusow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernice Matusow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernice Matusow. The network helps show where Bernice Matusow may publish in the future.

Co-authorship network of co-authors of Bernice Matusow

This figure shows the co-authorship network connecting the top 25 collaborators of Bernice Matusow. A scholar is included among the top collaborators of Bernice Matusow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernice Matusow. Bernice Matusow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Matusow, Bernice, Sadegh Saghafinia, Panyu Chen, et al.. (2024). OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC. Blood. 144(Supplement 1). 1908–1908. 1 indexed citations

Matusow, Bernice, Wayne Spevak, Yan Ma, et al.. (2024). Abstract 660: OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC. Cancer Research. 84(6_Supplement). 660–660.

Chen, Panyu, Bernice Matusow, James Tsai, et al.. (2024). Abstract 7264: OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models. Cancer Research. 84(6_Supplement). 7264–7264. 2 indexed citations

Duska, Linda, Dmitriy Zamarin, Erika Hamilton, et al.. (2023). Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. JCO Precision Oncology. 7(7). e2300235–e2300235. 6 indexed citations

Gordon, Michael S., Richard D. Carvajal, Alexander I. Spira, et al.. (2021). Phase 1b/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma.. Journal of Clinical Oncology. 39(15_suppl). 3018–3018. 4 indexed citations

Matusow, Bernice, et al.. (2021). Recent developments in predicting CYP-independent metabolism. Drug Metabolism Reviews. 53(2). 188–206. 9 indexed citations

Mims, Alice S., Melhem Solh, Jennifer N. Saultz, et al.. (2021). Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. Blood. 138(Supplement 1). 3420–3420. 2 indexed citations

Mims, Alice S., Melhem Solh, Uma Borate, et al.. (2020). Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. Blood. 136(Supplement 1). 14–15. 2 indexed citations

Pemmaraju, Naveen, Uma Borate, Melhem Solh, et al.. (2019). Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. Blood. 134(Supplement_1). 1391–1391. 4 indexed citations

10.

Gebreyohannes, Yemarshet K., Elizabeth A. Burton, Agnieszka Woźniak, et al.. (2018). PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors. Clinical and Experimental Medicine. 19(2). 201–210. 15 indexed citations

11.

Lin, Jack, Ying Zhang, Bernice Matusow, et al.. (2016). A Mixed Type 1 and Type 2 Kinase Inhibitor That Overrides FLT3 F691 and D835 Resistance Mutations. Blood. 128(22). 1074–1074. 2 indexed citations

12.

Elmore, Monica R. P., Allison R. Najafi, Maya A. Koike, et al.. (2014). Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain. Neuron. 82(2). 380–397. 1369 indexed citations breakdown →

13.

Mo, Yongkai, Orsi Giricz, Kimberly B. Dahlman, et al.. (2013). Abstract A26: Integrated epigenomic profiling reveals widespread demethylation in melanoma, and reveals aberrant CSF-1 receptor expression as a regulator of malignant growth and invasion inhibited by PLX3397. Cancer Research. 73(3_Supplement). A26–A26.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact